BioSpace News Archive

Panbela Therapeutics, Inc. announced the pricing of a public offering of 4,375,000 shares of its common stock or pre-funded warrants in lieu thereof and two classes of warrants to purchase up to an aggregate of 8,750,000 shares of its common stock at a purchase price of $2.06 per share and associated Common Warrants.

Cingulate Inc. announced that Werth Family Investment Associates, LLC, the manager of which is Peter J. Werth, a member of the Cingulate board of directors, has converted $3.3 million of debt and accrued interest into Cingulate equity at a conversion price of $4.785 per share.

Gracell Biotechnologies Inc. announced that the U.S. Food and Drug Administration has cleared Gracell’s Investigational New Drug application, allowing the Company to initiate a Phase 1 clinical trial of GC012F in the United States for the early-line treatment of multiple myeloma.

Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its fourth quarter and full year 2023 financial results before the market opens on Monday, March 11, 2024.

Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today outlined key 2024 strategic priorities and upcoming catalysts to support advancement of its clinical programs in RAS pathway-driven cancers.

Sarepta Therapeutics, Inc. today announced positive data from Part B of the MOMENTUM study (Study SRP-5051-201), a global, Phase 2, multi-ascending dose clinical trial of SRP-5051 (vesleteplirsen) that enrolled patients aged 8 to 21 years.

SciSparc Ltd. today announces the initiation of patient recruitment for its clinical trial in children suffering from autism spectrum disorder (“ASD”) at Soroka Medical Center in Israel.

Verrica Pharmaceuticals Inc. announced that the Centers for Medicare & Medicaid Services has issued a permanent J-Code for YCANTH™, which is the only FDA-approved treatment for molluscum contagiosum.

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable early efficacy results from the first patient enrolled in the Phase 1 Deltacel-01 clinical trial with Deltacel ™ for treating stage 4 metastatic non-small cell lung cancer (NSCLC).

Daxor Corporation today announces it will be exhibiting at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Mid-Winter and American College Nuclear Medicine (ACNM) Annual Meeting at the Hilton Orlando Lake Buena Vista in Orlando, FL, February 1-3, 2024.